Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 14;10(22):5292.
doi: 10.3390/jcm10225292.

Other (Non-CNS/Testicular) Extramedullary Localizations of Childhood Relapsed Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma-A Report from the ALL-REZ Study Group

Affiliations

Other (Non-CNS/Testicular) Extramedullary Localizations of Childhood Relapsed Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma-A Report from the ALL-REZ Study Group

Andrej Lissat et al. J Clin Med. .

Abstract

Children with other extramedullary relapse of acute lymphoblastic leukemia are currently poorly characterized. We aim to assess the prevalence and the clinical, therapeutic and prognostic features of extramedullary localizations other than central nervous system or testis in children with relapse of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) treated on a relapsed ALL protocol.

Patients and methods: Patients with relapse of ALL and LBL, treated according to the multicentric ALL-REZ BFM trials between 1983 and 2015, were analyzed for other extramedullary relapse (OEMR) of the disease regarding clinical features, treatment and outcome. Local treatment/irradiation has been recommended on an individual basis and performed only in a minority of patients.

Results: A total of 132 out of 2323 (5.6%) patients with ALL relapse presented with an OEMR (combined bone marrow relapse n = 78; isolated extramedullary relapse n = 54). Compared to the non-OEMR group, patients with OEMR had a higher rate of T-immunophenotype (p < 0.001), a higher rate of LBL (p < 0.001) and a significantly different distribution of time to relapse, i.e., more very early and late relapses compared to the non-OEMR group (p = 0.01). Ten-year probabilities of event-free survival (pEFS) and overall survival (pOS) in non-OEMR vs. OEMR were 0.38 ± 0.01 and 0.32 ± 0.04 (p = 0.0204) vs. 0.45 ± 0.01 and 0.37 ± 0.04 (p = 0.0112), respectively. OEMRs have been classified into five subgroups according to the main affected compartment: lymphatic organs (n = 32, 10y-pEFS 0.50 ± 0.09), mediastinum (n = 35, 10y-pEFS 0.11 ± 0.05), bone (n = 12, 0.17 ± 0.11), skin and glands (n = 21, 0.32 ± 0.11) and other localizations (n = 32, 0.41 ± 0.09). Patients with OEMR and T-lineage ALL/LBL showed a significantly worse 10y-pEFS (0.15 ± 0.04) than those with B-Precursor-ALL (0.49 ± 0.06, p < 0.001). Stratified into standard risk (SR) and high risk (HR) groups, pEFS and pOS of OEMR subgroups were in the expected range whereas the mediastinal subgroup had a significantly worse outcome. Subsequent relapses involved more frequently the bone marrow (58.4%) than isolated extramedullary compartments (41.7%). In multivariate Cox regression, OEMR confers an independent prognostic factor for inferior pEFS and pOS.

Conclusion: OEMR is adversely related to prognosis. However, the established risk classification can be applied for all subgroups except mediastinal relapses requiring treatment intensification. Generally, isolated OEMR of T-cell-origin needs an intensified treatment including allogeneic stem cell transplantation (HSCT) as a curative approach independent from time to relapse. Local therapy such as surgery and irradiation may be of benefit in selected cases. The indication needs to be clarified in further investigations.

Keywords: lymphoblastic leukemia; other extramedullary relapse; pediatric.

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interest. The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Ten-year pEFS (A) and pOS (B) of relapsed ALL patients differ significantly in OEMR vs. non-OEMR patients. The graphs have been calculated based on Kaplan–Meier analysis. p < 0.05.
Figure 2
Figure 2
Ten-year pEFS (A) and pOS (B) of SR vs. HR patients differ significantly in OEMR and non-OEMR patients. The graphs have been calculated based on Kaplan–Meier analysis. Pairwise log-rank test applied in subgroup analysis. p < 0.001.
Figure 3
Figure 3
Ten-year pEFS (AD) of OEMR patients in defined demographic subgroups. (A) T-ALL, (B) very early relapse and (C) combined BM relapse are correlated with significantly decreased 10-year pEFS. (D) Previous treatment protocol is not associated with outcome in OEMR patients. Calculation based on Kaplan–Meier analysis. p < 0.05.
Figure 4
Figure 4
Ten-year pEFS (A,B) and pOS (C,D) of OEMR subgroups; (A,C): pEFS and pOS of combined bone marrow and isolated OEMR; (B,D): pEFS and pOS of isolated OEMR. Mediastinal and bone OEMR demonstrate inferior outcome compared to all other subgroups. Calculation based on Kaplan–Meier analysis. p < 0.05.
Figure 5
Figure 5
Ten-year pEFS (A) and pOS (B) of OEMR subgroups stratified by HR and SR criteria. HR OEMR is associated with significantly decreased 10-year pEFS and pOS except in mediastinal subgroup. Calculation based on Kaplan–Meier analysis. Pairwise log-rank applied in subgroup analysis. p < 0.05.

Similar articles

Cited by

References

    1. Gaudichon J., Jakobczyk H., Debaize L., Cousin E., Galibert M.D., Troadec M.B., Gandemer V. Mechanisms of extramedullary relapse in acute lymphoblastic leukemia: Reconciling biological concepts and clinical issues. Blood Rev. 2019;36:40–56. doi: 10.1016/j.blre.2019.04.003. - DOI - PubMed
    1. Pui C.H. Central nervous system disease in acute lymphoblastic leukemia: Prophylaxis and treatment. Hematol. Am. Soc. Hematol. Educ. Program. 2006;2006:142–146. doi: 10.1182/asheducation-2006.1.142. - DOI - PubMed
    1. Wofford M.M., Smith S.D., Shuster J.J., Johnson W., Buchanan G.R., Wharam M.D., Ritchey A.K., Rosen D., Haggard M.E., Golembe B.L., et al. Treatment of occult or late overt testicular relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study. J. Clin. Oncol. 1992;10:624–630. doi: 10.1200/JCO.1992.10.4.624. - DOI - PubMed
    1. Murray J.C., Gmoser D.J., Barnes D.A., Oshman D., Hawkins H.K., Gresik M.V., Dreyer Z.E. Isolated bone relapse during hematologic remission in childhood acute lymphoblastic leukemia: Report of a metatarsal relapse and review of the literature. Med. Pediatr. Oncol. 1994;23:153–157. doi: 10.1002/mpo.2950230217. - DOI - PubMed
    1. Padmanjali K.S., Bakhshi S., Thavaraj V., Karak A.K., Arya L.S. Bone relapse in acute lymphoblastic leukemia. Indian J. Pediatr. 2004;71:555–557. doi: 10.1007/BF02724304. - DOI - PubMed